MEETING CHANGE TO VIRTUAL: Hepatobiliary Cancers: Pathobiology and Translational Advances
joint with MEETING CHANGE TO VIRTUAL: Fatty Liver Disease and Multi-System Complications
Scientific Organizers: Alphonse E. Sirica, Gregory J. Gores and Lopa Mishra
Date: March 21 - 24, 2021
Location: Virtual at your computer
For important information on the coronavirus, please click here
For information on the virtual eSymposia program Click here
Hepatobiliary cancers, including hepatocellular carcinomas (HCC) and intrahepatic cholangiocarcinomas (iCCA), represent a major global health burden, with hepatobiliary cancers being the second or third leading cause of cancer mortality worldwide. Moreover, with the rising trends in emerging cases, this field continues to challenge biological researchers and clinicians. This Keystone Symposia conference will be the first of its kind to focus specifically on this challenging disease. The conference aims to integrate emerging basic and translational research with the clinical perspective, in order to advance our understanding of the pathobiology behind both HCC and iCCA, with the ultimate goal of guiding novel treatment and prevention strategies targeting these underlying mechanisms. The program will explore current challenges in the field, including (1) shifting etiological trends, focusing on mechanisms linked to cell injury, inflammation, and fibrogenesis; (2) roles of the microbiome and tumor microenvironment in affecting disease progression, therapeutic resistance, and immunosurveillance; (3) challenges of inter- and intra-tumoral heterogeneity; (4) identification of novel and more effective biomarker signatures for monitoring prognosis and treatments; (5) advances in “omics” for personalizing therapies; and (6) current and emerging trends in molecular and immune targeting. Moreover, this unique conference is being paired with a joint meeting entitled Fatty Liver Disease and Multi-System Complications, which is highly complementary in view of the fact that non-alcoholic steatohepatitis is an important risk factor for hepatobiliary cancer. These joint meetings will foster new and productive research collaborations towards both basic and translational advances, as well as offer valuable training opportunities for basic researchers and physician scientists.